CR20140002A - Bloqueantes de los canales de sodio dependientes de voltaje - Google Patents

Bloqueantes de los canales de sodio dependientes de voltaje

Info

Publication number
CR20140002A
CR20140002A CR20140002A CR20140002A CR20140002A CR 20140002 A CR20140002 A CR 20140002A CR 20140002 A CR20140002 A CR 20140002A CR 20140002 A CR20140002 A CR 20140002A CR 20140002 A CR20140002 A CR 20140002A
Authority
CR
Costa Rica
Prior art keywords
blockers
sodium channels
voltage dependent
dependent sodium
compounds
Prior art date
Application number
CR20140002A
Other languages
English (en)
Inventor
Jeffrey Charles Boehm
Roderick S Davis
Jeffrey Kerns
Guoliang Lin
Robert D Murdoch
Hong Nie
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47437403&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20140002(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CR20140002A publication Critical patent/CR20140002A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En general, la presente invención se refiere a usos de compuestos bloqueantes de los canales de sodio dependientes de voltaje, que incluyen los precursores correspondientes, intermedios, 5 monómeros y dímeros, a composiciones farmacéuticas correspondientes, a la preparación de compuestos y a métodos de tratamiento para enfermedades respiratorias y del tracto respiratorio
CR20140002A 2011-07-06 2014-01-06 Bloqueantes de los canales de sodio dependientes de voltaje CR20140002A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161505075P 2011-07-06 2011-07-06

Publications (1)

Publication Number Publication Date
CR20140002A true CR20140002A (es) 2014-03-05

Family

ID=47437403

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140002A CR20140002A (es) 2011-07-06 2014-01-06 Bloqueantes de los canales de sodio dependientes de voltaje

Country Status (21)

Country Link
US (1) US20140121213A1 (es)
EP (1) EP2729149A4 (es)
JP (1) JP2014518281A (es)
KR (1) KR20140059774A (es)
CN (1) CN103764148A (es)
AR (1) AR087053A1 (es)
AU (1) AU2012279091A1 (es)
BR (1) BR112014000259A2 (es)
CA (1) CA2840394A1 (es)
CL (1) CL2014000020A1 (es)
CO (1) CO6821963A2 (es)
CR (1) CR20140002A (es)
DO (1) DOP2014000001A (es)
EA (1) EA201490210A1 (es)
MA (1) MA35336B1 (es)
MX (1) MX2014000112A (es)
PE (1) PE20141385A1 (es)
PH (1) PH12014500006A1 (es)
TW (1) TW201302707A (es)
WO (1) WO2013006596A1 (es)
ZA (1) ZA201309533B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013122897A1 (en) 2012-02-13 2013-08-22 Amgen Inc. Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
WO2013134518A1 (en) 2012-03-09 2013-09-12 Amgen Inc. Sulfamide sodium channel inhibitors
EP2974730B1 (en) * 2013-03-14 2018-01-31 Daiichi Sankyo Company, Limited Drug for respiratory diseases
US10668067B2 (en) 2016-07-20 2020-06-02 Amgen Inc. Pyridine sulfonamides
JP7497357B2 (ja) * 2018-12-13 2024-06-10 インターベット インターナショナル ベー． フェー． １－［（３ｒ，４ｓ）－４－シアノテトラヒドロピラン－３－イル］－３－［（２－フルオロ－６－メトキシ－４－ピリジル）アミノ］ピラゾール－４－カルボキサミドの調製方法
CN109796402A (zh) * 2018-12-28 2019-05-24 京博农化科技有限公司 一种烟嘧磺隆中间体2-氯-n，n-二甲基烟酰胺的制备方法
US12054486B2 (en) 2021-09-24 2024-08-06 Xenon Pharmaceuticals Inc. Pyridine derivatives and their use as sodium channel activators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008147864A2 (en) * 2007-05-22 2008-12-04 Xenon Pharmaceuticals Inc. Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions
TW201139406A (en) * 2010-01-14 2011-11-16 Glaxo Group Ltd Voltage-gated sodium channel blockers

Also Published As

Publication number Publication date
BR112014000259A2 (pt) 2017-02-14
EP2729149A4 (en) 2015-01-07
AR087053A1 (es) 2014-02-12
PE20141385A1 (es) 2014-10-29
CA2840394A1 (en) 2013-01-10
KR20140059774A (ko) 2014-05-16
MA35336B1 (fr) 2014-08-01
EA201490210A1 (ru) 2014-05-30
DOP2014000001A (es) 2014-04-30
AU2012279091A1 (en) 2014-01-16
PH12014500006A1 (en) 2014-02-10
ZA201309533B (en) 2014-08-27
US20140121213A1 (en) 2014-05-01
TW201302707A (zh) 2013-01-16
CN103764148A (zh) 2014-04-30
CO6821963A2 (es) 2013-12-31
EP2729149A1 (en) 2014-05-14
CL2014000020A1 (es) 2014-08-01
JP2014518281A (ja) 2014-07-28
WO2013006596A1 (en) 2013-01-10
MX2014000112A (es) 2014-01-31

Similar Documents

Publication Publication Date Title
CR20120402A (es) Bloqueantes de los canales de sodio dependientes de voltaje
CR20140002A (es) Bloqueantes de los canales de sodio dependientes de voltaje
UY39646A (es) Procedimiento para la preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
BR112015022096A2 (pt) moduladores de canal de sódio para o tratamento da dor
MX346143B (es) Ligandos del receptor ep1.
MX2014013858A (es) Metodo para tratar un cancer positivo de gd2.
EA201490420A1 (ru) ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С α-СУБЪЕДИНИЦАМИ ПОТЕНЦИАЛЗАВИСИМЫХ НАТРИЕВЫХ КАНАЛОВ (SCNxA), С ПОМОЩЬЮ МАЛЫХ МОЛЕКУЛ
CR20130371A (es) IMIDAZO[5,1-f][1,2,4]TRIAZINAS PARA EL TRATAMIENTO DE TRASTORNOS NEUROLÓGICOS
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
MX388946B (es) Esteroides neuroactivos sustituidos con 19-alcoxi-17, profarmacos de los mismos, y metodos de tratamiento usando los mismos.
CO6821960A2 (es) Benzoxazepinonas fusionadas como moduladoras de canales iónicos
EA201391561A1 (ru) Новые соединения-модуляторы gpr-119
ECSP12012171A (es) Composiciones farmacéuticas del compuesto espiro-oxindol para administración tópica y sus usos como agentes terapéuticos
BR112014012230A2 (pt) fralda de vestir descartável de tamanho pequeno
MX353482B (es) Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor.
DOP2016000276A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
CR20140513A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
BR112014018879A8 (pt) Composto e composição farmacêutica e combinação compreendendo dito composto
MX355267B (es) Análogos de carba-nucleósido 2´-sustituidos para tratamiento antivírico.
SV2011003802A (es) Derivados de triazol utiles para el tratamiento de enfermedades
CO6700831A2 (es) Derivados de pirazina como bloqueadores de enac
MX2013015274A (es) Anatagonista trpm8 y su uso en tratamientos.
EP2912013A4 (en) METHOD FOR PRODUCING GALLENIC ACID DERIVATIVES
EA201590381A1 (ru) Замещенные пиразолы, используемые в качестве блокаторов кальциевых каналов n-типа